In addition, collaboration with renal medicine is essential to avoid introduction of dialysis. Also we should consider how we could help patients by treatment to live long actively in the society. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Dispenzieri A, et al. Treatment of newly diagnosed NCT-501 concentration multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323–41.PubMed 2. Bergsagel DE, et al. Myeloma proteins and the clinical response to melphalan therapy. Science. 1965;148(3668):376–7. 3. Salmon SC, et al. Intermittent
FRAX597 manufacturer high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179–87.PubMed 4. Alexanian R, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680–5.PubMedCrossRef 5. Kyle RA, et al. A long-term study of prognosis AZD1480 cost in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.PubMedCrossRef 6. San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17. 7. Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.PubMedCrossRef 8. Hideshima T, et al. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005;11(24 Pt 1):8530–3.PubMedCrossRef 9. Fayers PM, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239–47.PubMedCrossRef 10. Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98. 11. San Miguel JF, et
al. ASH2011. http://myeloma.org/pdfs/ASH2011_San%20Miguel_3619.pdf. 12. Suzuki K. Discovery research on the effects of giving continuity to the administration of bortezomib in maintenance therapy to target of relapsed and refractory multiple myeloma. J New Rem Clin. Florfenicol 2012;61:1259–69. 13. Durie BGM, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. 14. Niesvizky R, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46–53.PubMedCrossRef 15. Harousseau JL, et al. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139–46.PubMedCrossRef 16. Chanan-Khan A, et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612–24.PubMedCrossRef 17.